Comparative analysis on price negotiation models of patented drugs in Korea and Germany and its implications for China
10.3969/j.issn.1674-2982.2015.10.012
- VernacularTitle:韩国和德国专利药价格谈判模式比较研究及启示
- Author:
Lin WU
;
Yongfa CHEN
- Publication Type:Journal Article
- Keywords:
Patented drug;
Price negotiation;
Drug reimbursement;
Technical assessment
- From:
Chinese Journal of Health Policy
2015;(10):62-67
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To provide policy recommendations for improving price negotiation system of patented drugs in China. Methods: This paper comparatively analyzes the commonalities and characteristics between Korea’ and Germany’s price negotiation models for patented drugs from three aspects of their goals, procedures and effects. Results:The key objective of both Korea’ and Germany’s price negotiation systems for patented drugs is to efficiently improve the utilization of national health insurance services, and responsibilities are properly assigned among differ-ent institutions to ensure the equity and efficiency of negotiations. However, due to the differences in national cir-cumstances, there is a big difference in the selection of technical assessment criteria. Conclusion: This paper sug-gests China to strengthen the convergence between price negotiations for patented drugs and medical insurance reim-bursement policy, to establish a technical assessment system with the innovation extent for patented drugs as its core, and to develop scientific and rational negotiation procedures and division of responsibilities as well.
